.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Daiichi Sankyo
McKesson
Cantor Fitzgerald
Cerilliant
Moodys
Deloitte
Accenture
QuintilesIMS
Chubb

Generated: February 20, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 0601082.1

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
NovartisAFINITOReverolimusTABLET;ORAL022334-001Mar 30, 2009RXYesNo➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-002Mar 30, 2009RXYesYes➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-003Jul 9, 2010RXYesNo➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
NovartisAFINITOReverolimusTABLET;ORAL022334-004Mar 30, 2012RXYesNo➤ Try a Free Trial➤ Try a Free TrialTREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist